| Literature DB >> 35463562 |
Panagiotis Papadopoulos1, Stelios Iordanou1, Fotini Georgiou1, Dimitris Kalifatidis1, Elena Herodotou1, Chrystalla Timiliotou-Matsentidou1.
Abstract
Povidone-iodine (PI) is considered a generally safe broad-spectrum, antiseptic substance, which is widely used in healthcare services, mostly for burn patients, in wound treatment, surgical wound irrigation, as well as for a few gynecological indications. Although it is safe, its use on mucosa can cause toxicity due to iodine absorption and the high concentration in the serum. PI toxicity is absorption depended and has been associated with severe adverse events including acute kidney injury (AKI). To our knowledge, there are only three cases of PI-induced AKI after uterine instillation in the published literature. We report a case of severe PI-induced AKI that occurred in a 23-year-old female due to iodine systemic absorption immediately post uterine instillation, in terms of infertility evaluation. The patient was admitted to the intensive care unit (ICU), supported with mechanical ventilation and treated with renal replacement therapy (RRT). Renal function and urine output improved and the patient was discharged from ICU. Severe adverse events may be linked to internal use, therefore, PI on mucosa should be used with extreme caution. Clinicians should be aware of iodine intoxication and possible AKI.Entities:
Keywords: acute kidney injury; aki; anuria; hydrotubation; povidone-iodine
Year: 2022 PMID: 35463562 PMCID: PMC9001871 DOI: 10.7759/cureus.24034
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Summary table of patient’s full blood count, biochemistry and clotting test results during the first nine days of her ICU hospitalization.
WBC: White blood cells, NEUT: Neutrophils, LYM: Lymphocytes, MONO: Monocytes, EOS: Eosinophils, BASO: Basophils, IG: Immature Granulocytes, RBC: Red Blood Cells, HGB: Hemoglobin, HCT: Hematocrit, MCV: Mean Corpuscular Volume, MCH: Mean Cell Hemoglobin, PLT: Platelets, MPV: Mean Platelet Volume, LDH: Lactate dehydrogenase, CRP: C-reactive protein, PT: Prothrombin Time, INR: International Normalized Ratio, APTT: Activated Partial Thromboplastin Time, TBIL: Total bilirubin, ALP: Alkaline phosphatase, γ-GT: Gamma-glutamyl Transferase, ALT, SGPT: Alanine aminotransferase, AST, SGOT: Aspartate aminotransferase, L: Litre
| Laboratory | ICU Admission Day | DAY 1 | DAY 2 | DAY 3 | DAY 4 | DAY 5 | DAY 6 | DAY 7 | DAY 8 | DAY 9 |
| WBC (103/μL) | 45.06 | 36.00 | 21.33 | 16.58 | 16.02 | 15.56 | 14.64 | 11.55 | 13.71 | 18.91 |
| NEUT (%) | 95.8 | 87.9 | 78.1 | 67.5 | 69.4 | 67.4 | 61.1 | 63.4 | 77.4 | 77.3 |
| LYM (%) | 2.3 | 8.5 | 13.6 | 7.5 | 10.9 | 13.9 | 17.6 | 20.8 | 11.9 | 13.6 |
| MONO (%) | 1.8 | 3.4 | 4.6 | 7.5 | 10.2 | 10.5 | 10.9 | 10.9 | 8.9 | 8.0 |
| EOS (%) | 0.0 | 0.1 | 3.5 | 8.2 | 9.1 | 7.8 | 9.9 | 4.6 | 1.4 | 0.8 |
| BASO (%) | 0.1 | 0.1 | 0.2 | 0.4 | 0.4 | 0.4 | 0.5 | 0.3 | 0.4 | 0.3 |
| IG (%) | 0.9 | 0.8 | 0.9 | 1 | 1.4 | 1.7 | 2.4 | 1.7 | 1.2 | 0.8 |
| NEUT (103/μL) | 43.19 | 31.66 | 16.65 | 11.19 | 11.11 | 10.48 | 8.95 | 7.33 | 10.62 | 14.60 |
| LYM (103/μL) | 1.03 | 3.05 | 2.90 | 2.72 | 1.75 | 2.16 | 2.57 | 2.40 | 1.63 | 2.58 |
| MONO (103/μL) | 0.79 | 1.22 | 0.99 | 1.24 | 1.64 | 1.63 | 1.60 | 1.26 | 1.22 | 1.51 |
| EOS (103/μL) | 0.01 | 0.04 | 0.74 | 1.36 | 1.46 | 1.22 | 1.45 | 0.53 | 0.19 | 0.16 |
| BASO (103/μL) | 0.04 | 0.03 | 0.05 | 0.07 | 0.06 | 0.07 | 0.07 | 0.03 | 0.05 | 0.06 |
| IG (103/μL) | 0.42 | 0.27 | 0.19 | 0.16 | 0.23 | 0.26 | 0.35 | 0.20 | 0.16 | 0.16 |
| RBC (103/μL) | 3.67 | 3.13 | 2.63 | 2.69 | 2.79 | 2.72 | 2.68 | 2.58 | 2.60 | 2.60 |
| HGB (g/dL) | 10.4 | 8.9 | 7.5 | 7.7 | 8.1 | 7.8 | 7.7 | 7.4 | 7.4 | 7.4 |
| HCT (%) | 31.6 | 26.8 | 22.7 | 23.7 | 24.5 | 24 | 23.9 | 22.8 | 23.2 | 23.4 |
| MCV (fL) | 86.1 | 85.6 | 86.3 | 88.1 | 87.8 | 88.7 | 89.2 | 88.4 | 89.2 | 90 |
| MCH (pg) | 28.3 | 28.4 | 28.5 | 28.6 | 29 | 28.7 | 28.7 | 28.7 | 28.5 | 28.5 |
| PLT (103/μL) | 190 | 133 | 88 | 109 | 117 | 160 | 232 | 304 | 360 | 537 |
| MPV (fL) | 11.1 | 10.9 | 10.2 | 10.1 | 9.6 | 10.2 | 9.9 | 9.4 | 9.1 | 9.6 |
| CRP (mg/L) | 123 | 107.96 | 85.61 | 84.05 | 91.62 | 89.26 | 63.58 | 28.32 | 36.97 | |
| LDH | 3319 | 2104 | 1172 | 792 | 634 | 590 | 575 | 729 | 740 | |
| TBIL (mg/dL) | 0.97 | 0.60 | 0.72 | 0.50 | 0.55 | |||||
| ALP (U/L) | 159 | 78 | 57 | 63 | 63 | 13 | 71 | 76 | ||
| γ-GT (U/L) | 22 | 16 | 14 | 40 | 33 | 34 | 49 | 47 | ||
| ALT, SGPT (U/L) | 25 | 36 | 49 | 26 | 19 | 14 | 40 | 21 | ||
| AST, SGOT (U/L) | 124 | 69 | 40 | 18 | 15 | 13 | 45 | 27 | ||
| Urea (mg/dL) | 79 | 51 | 22 | 18 | 25 | 32 | 26 | 42 | 83 | |
| Creatinine | 3.04 | 2.02 | 1.26 | 1.25 | 1.34 | 1.64 | 1.41 | 2.03 | 4.07 | |
| Fibrinogen (mg/dL) | 292 | 302 | 306 | 473 | 447 | 467 | ||||
| PT (sec) | 14.9 | 13 | 13.3 | 12.9 | 12.6 | 13.9 | 12.1 | 13.3 | ||
| INR | 1.36 | 1.14 | 1.16 | 1.13 | 1.10 | 1.23 | 1.05 | 1.17 | ||
| APTT (sec) | 37.62 | 38.71 | 40.51 | 41.39 | 37.19 | 40.34 | 39.69 | 42.83 |
Figure 1Computed tomography (CT) scan of the chest and abdomen-pelvis
CT showed heterogeneous uterine density and moderate diffuse endometrial thickening.
Figure 2Patient clinical course